Evidence map›Paper›PMID 25784779›Full record

ArticleDisease markers2015

Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal disease.

Chia-Ter Chao, Yen-Ching Chen, Chih-Kang Chiang, Jenq-Wen Huang, Fu-Chang Hu, Cheng-Chung Fang, Chen-Chih Chang, Chung-Jen Yen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chia-Ter ChaoDepartment of Internal Medicine, National Taiwan University Hospital, Jinshan branch, No. 51, Nanshih, Jinshan district, New Taipei 20844, Taiwan ; Graduate Institute of Toxicology, National Taiwan University, No. 1, Jen-Ai Road Section 1, Taipei 10051, Taiwan.ORCID 0000-0003-2892-7986
Yen-Ching ChenInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 17, Hsu-Chow Road, Taipei 10055, Taiwan.
Chih-Kang ChiangDepartment of Internal Medicine, National Taiwan University Hospital, Jinshan branch, No. 51, Nanshih, Jinshan district, New Taipei 20844, Taiwan ; Graduate Institute of Toxicology, National Taiwan University, No. 1, Jen-Ai Road Section 1, Taipei 10051, Taiwan ; Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan ; Department of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Jenq-Wen HuangDepartment of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Fu-Chang HuGraduate Institute of Clinical Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Cheng-Chung FangDepartment of Emergency Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Chen-Chih ChangDepartment of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Chung-Jen YenDepartment of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan ; Department of Geriatric Medicine and Gerontology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPPAR-γ single nucleotide polymorphisms (SNPs) reportedly play an important role in determining metabolic risk among diverse population. Whether PPAR-γ SNPs affect the clinical courses in ESRD patients is unknown.

methodsFrom a multicenter cohort, we identified 698 patients with prevalent ESRD between 2002 and 2003, and other 782 healthy subjects as control. Two PPAR-γ SNPs, Pro12Ala (rs1801282) and C161T (rs3856806), were genotyped and their association with ESRD was examined. Both groups were prospectively followed until 2007, and the predictability of genotypes for the long-term survival of ESRD patients was analyzed.

resultsAfter multivariable-adjusted regression, GG genotype of Pro12Ala was significantly more likely to associate with ESRD (P < 0.001) among patients with non-diabetes-related ESRD. Cox's proportional hazard regression showed that both Pro12Ala and C161T polymorphisms were significant predictors of mortality in ESRD patients with DM (Pro12Ala: GG versus other genotypes, hazard ratio [HR] <0.01; P < 0.001; for C161T, CC versus TT genotypes, HR 2.86; P < 0.001; CT versus TT genotypes, HR 1.93; P < 0.001).

conclusionThis is the first and largest study to evaluate PPAR-γ SNPs in ESRD patients. Further mechanistic study is needed to elucidate the role of PPAR-γ among ESRD patients.

Indexed as

Polymorphism, Single NucleotideAgedCase-Control StudiesDiabetic NephropathiesFemaleHumansKidney Failure, ChronicMaleMiddle AgedMutation, MissensePPAR gammaPPAR gamma

Identifiers

PMID25784779
PMCPMC4345048
OpenAlexW2089110231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.